Drug Approval | May 03, 2025
Neuland Laboratories completes USFDA inspection at Unit 2
The FDA issued Form 483 with one observation related to building and facility management
The FDA issued Form 483 with one observation related to building and facility management
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The Subsidiary has received one inspectional observation in Form 483
Investment demonstrates confidence in America’s commitment to science and innovation
The inspection concluded with 6 observations and none of them were related to Data Integrity
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation
Subscribe To Our Newsletter & Stay Updated
